QR код

ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance

Introduction: ALK-positive lung cancers represent a molecularly diverse disease. With drug exposure, driving selection pressure, and resistance pathways, disease relapse will emerge. There is compelling rationale to investigate novel treatment strategies, informed by dynamic circulating tumor DNA (c...

Повний опис

Збережено в:
Автори: Malinda Itchins, BMedSci, M.B.B.S., FRACP, PhD, Shirley Liang, BSc, Chris Brown, MBiostats, BSc, Tristan Barnes, BSc (Med), M.B.B.S., FRACP, Gavin Marx, BSc, M.B.B.S., FRACP, Venessa Chin, M.B.B.S., FRACP, PhD, Steven Kao, BHB, MBChB, PhD, FRACP, Po Yee Yip, MBChB, FRACP, PhD, Antony J. Mersiades, BMedSc, M.B.B.S., FRACP, MMed (Clin. Epi), Adnan Nagrial, M.B.B.S., FRACP, PhD, Victoria Bray, M.B.B.S., FRACP, PhD, Geoffrey Peters, BPharm, M.B.B.S., FRACP, Sagun Parakh, BSc, MBChB, FRACP, PhD, Kavita Garg, PhD, Bob T. Li, MD, PhD, MPH, Matthew McKay, PhD, Kenneth O'Byrne, M.B.B.S., FRACP, FRCPA, MD, Thomas John, M.B.B.S., FRACP, PhD, Anthony J. Gill, MD, FRCPA, Mark P. Molloy, PhD, Benjamin J. Solomon, M.B.B.S., FRACP, PhD, Nick Pavlakis, BSc, M.B.B.S., MMed (Clin. Epi), PhD, FRACP
Формат: Artigo
Мова:Inglês
Опубліковано: Elsevier 2024-09-01
Серія:JTO Clinical and Research Reports
Предмети:
ALK
ALKi
NSCLC
Resistance
ctDNA
Lorlatinib
Онлайн доступ:http://www.sciencedirect.com/science/article/pii/S2666364324000730
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси